Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation

New Microbiologica

Volumn 34, Issue 1, 2011, Pages 33-36

  Solidoro, Paolo ^a   Delsedime, Luisa ^a   Costa, Cristina ^a   Bergallo, Massimiliano ^a   Libertucci, Daniela ^a   Ruffini, Enrico ^b   Rinaldi, Mauro ^c   Baldi, Sergio ^a  

^a Divisions of Pneumology ^*  (Italy)

^b Divisions of Thoracic Surgery   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

CMV immunoglobulin; Lung transplantation; Pneumonia; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; IMMUNOGLOBULIN; VALGANCICLOVIR;

ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOLOGY; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATION; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS PNEUMONIA;

ACYCLOVIR; ANTIVIRAL AGENTS; BIOPSY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; LUNG TRANSPLANTATION; PNEUMONIA, VIRAL; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME;

CYTOMEGALOVIRUS;

EID: 79952480236     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Duncan A.J., Dummer J.S., Paradis I.L., et al. (1991). Cytomegalovirus infection and survival in lung transplant recipients. 7. Heart Lung Transplant. 10, 638.
2. Everett J.P., Hersberger R.E., Norman D.J., et al. (1992). Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J. Heart Lung Transplant. 11, S133
3. Pereyra E, Rubin R.H. (2004). Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin. Infect. Dis. 17, 357.
4. Pober J.S., Cotran R.S. (1990). Cytokines and endothelial cell biology. Physiol. Rev. 70, 427-451. (Pubitemid 20140187)
5. Ruttman E., Geltner C, Bucher B., Ulmer H., Hofer D., Hangler H.B., et al. (2006). Combined CMV prophylaxis improves outcome and reduces the risk for Bronchiolitis Obliterans Syndrome (BOS) after lung transplantation. Transplantation. 10, 1415-1420. (Pubitemid 43847152)
6. Sharples L.D., McNeil K., Stewart S., Wallwork J. (2002). Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung. Transplant. 21, 271.
7. Sia I.G., Patel R. (2000). New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13, 83-121. (Pubitemid 30039345)
8. Solidoro P., Libertucci D., Delsedime L., Ruffini E., Bosco M., Costa C, et al. (2008). Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchi-tis/bronchiolitis, and herpesvirus infections. Transplantation Proceedings. 40, 2013-2014.
9. Tamm M., Aboyoun C.L., Chhajed P.N., et al. (2004). Treated cytomegalovyrus pneumonia is associated with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 170, 1120-1123. (Pubitemid 39488626)
10. Tamm M., Aboyoun C.L., Chhajed P.N., Rainer S., Malouf M.A., Glanville A.R. (2004). Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 170, 1120.
11. Tikkanen J.M., Krebs R., Bruggeman C, et al. (2004). Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allograft. Transplantation. 77, 655-658. (Pubitemid 38366967)
12. Valantine H.A., Luikart H., Dovle R., et al. (2001). Impact of cytomegalovirus hyperimmune globu-line on outcome after cardiothoracic transplantation. Transplantation. 72, 1642-1652.
13. Waldman W.J., Knight D.A. (1996). Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cy-tomegalovirus-activated T cells. American Jumal of Pathology. 148, 1: 105-119. (Pubitemid 26019649)
14. Waldman W.J., Knight D.A., Adams P.W., Orosz C.G., SedmakD.D. (1993). In vitro induction of endothelial HLA class II antigen expression by CMV-acti-vated CD4+ T cells. Transplantation. 56, 1504-1512. (Pubitemid 24018813)
15. Weill D., Lock B.J., Wewers D.L., et al. (2003). Combination prophylaxis with ganciclovir (CMV) immune globuline after lung transplantation: effective CMV prevention following daclizumab. Am. J. Transplantation. 3, 492-496. (Pubitemid 36560103)
16. Zamora M.R., Nicolls M.R., Hodges T.N., et al. (2004). Following universial prophylaxis with intravenous ganciclovir and Cytomegalovirus immune globulin, Vlaganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Transplantation. 77, 655-658.